Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07106762 · ClinicalTrials.gov registry record · Phase 2
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
A Phase 2 study of Urothelial Cancer, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 470
- Enrollment target
- 20
- Study locations
NCT07106762: Recruiting Phase 2 study of Urothelial Cancer, sponsored by Bristol-Myers Squibb.
NCT07106762 is a Phase 2 study of Urothelial Cancer that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 470 participants, below the 556-participant average among 25 other Urothelial Cancer trials with a reported enrollment target (15% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07106762, a Phase 2 study of Urothelial Cancer, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 470 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or After Immunotherapy
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Gemcitabine
- DRUG Iza-bren
Study Locations (20)
California
- Local Institution - 0162 - Fullerton
- Local Institution - 0252 - Palo Alto
- Local Institution - 0163 - Sacramento
- Local Institution - 0139 - Sacramento
- Local Institution - 0251 - San Francisco
- Local Institution - 0254 - Santa Rosa
New York
- Local Institution - 0248 - Buffalo
- Icahn School of Medicine at Mount Sinai - New York
- Memorial Sloan Kettering Cancer Center - New York
Colorado
- Local Institution - 0245 - Dillon
- Shaw Cancer Center - Edwards
Ohio
- Fairview Hospital - Cleveland
- Cleveland Clinic - Cleveland
Arizona
- Local Institution - 0167 - Gilbert
District of Columbia
- Local Institution - 0250 - Washington D.C.
Florida
- Local Institution - 0247 - Miami
Kentucky
- Local Institution - 0193 - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 470 participants |
| Start Date | 2025-09-30 |
| Est. Completion | 2033-11-18 |
| Phase | Phase 2 |
What NCT07106762 shows while recruiting
NCT07106762 is an interventional study that assigns participants to a tested intervention. The registered 470 participants enrollment target is mid-sized for trials with a published cap, below the 556-participant average among 25 other Urothelial Cancer trials with a reported enrollment target (15% lower).
The record links to 1 condition, with Urothelial Cancer appearing as the primary indexed condition, and to 4 interventions - of which Carboplatin is the first listed.
NCT07106762 names 20 study sites across 11 states, led by California, New York, Colorado.
Frequently Asked Questions
What is clinical trial NCT07106762 about?
NCT07106762 is a clinical study titled "Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy". A Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or After Immunotherapy
What is the current status of trial NCT07106762?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 470 participants. The study started on 2025-09-30. Estimated completion is 2033-11-18.
What conditions does trial NCT07106762 study?
This clinical trial studies the following conditions: Urothelial Cancer.
What interventions are being tested in trial NCT07106762?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Gemcitabine (DRUG), Iza-bren (DRUG).
Who is sponsoring clinical trial NCT07106762?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07106762 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urothelial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07106762's enrollment target sits among peer trials
470 11th of 25 higher than 15 of 25 other Urothelial Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Urothelial Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
RECRUITING · Phase 2
-
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
RECRUITING · Phase 2
-
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer
ACTIVE NOT RECRUITING · Phase 2
-
An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05256940 · 470 participants · NA
Motivational Interviewing to Address Suicidal Ideation for Veterans at High Risk for Suicide
- NCT05458219 · 470 participants · Phase 1
A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
- NCT05850689 · 470 participants · Phase 3
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- NCT05935384 · 470 participants
SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI